Based on MYO1G promoter methylation defined by the mean methylation level of the 4 CpG sites, we also observed the melanoma patients belonging to low methylation group have longer overall survival (P=0.005) than those belonging to high methylation group (Figure 2E). The gene discussed is MYO1G; the disease is melanoma.